ID: ALA372208

Max Phase: Preclinical

Molecular Formula: C28H25N5O3

Molecular Weight: 479.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOc1cccc(-n2c(=O)n(C)c3ccc(C(O)(c4ccc(C#N)cc4)c4cncn4C)cc32)c1

Standard InChI:  InChI=1S/C28H25N5O3/c1-4-36-23-7-5-6-22(15-23)33-25-14-21(12-13-24(25)32(3)27(33)34)28(35,26-17-30-18-31(26)2)20-10-8-19(16-29)9-11-20/h5-15,17-18,35H,4H2,1-3H3

Standard InChI Key:  RJENTGJJWOWPMM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 479.54

Molecular Weight (Monoisotopic): 479.1957

AlogP: 3.62

#Rotatable Bonds: 6

Polar Surface Area: 98.00

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.13

CX Basic pKa: 5.95

CX LogP: 3.64

CX LogD: 3.63

Aromatic Rings: 5

Heavy Atoms: 36

QED Weighted: 0.40

Np Likeness Score: -1.27

References

1. Li Q, Li T, Woods KW, Gu WZ, Cohen J, Stoll VS, Galicia T, Hutchins C, Frost D, Rosenberg SH, Sham HL..  (2005)  Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.,  15  (11): [PMID:15911281] [10.1016/j.bmcl.2005.03.049]

2. Equbal T, Silakari O, Rambabu G, Ravikumar M..  (2007)  Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.,  17  (6): [PMID:17236767] [10.1016/j.bmcl.2006.12.087]

Source

Source(1):

• Scientific Literature